Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report

Therapeutic Drug Monitoring

Volumn 21, Issue 5, 1999, Pages 580-582

  Skogh, Elisabeth ^a   Bengtsson, Finn ^a   Nordin, Conny ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse event; Clozapine; Cytochrome P 450; Smoking; Therapeutic drug monitoring

Indexed keywords

CLOZAPINE; OXAZEPAM;

ADULT; ARTICLE; CASE REPORT; COMA; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG METABOLISM; DRUG MONITORING; ENZYME INDUCTION; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; SMOKING CESSATION;

ADULT; CLOZAPINE; HUMANS; MALE; SCHIZOPHRENIA; SEIZURES; SMOKING CESSATION;

EID: 0032851490     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199910000-00016     Document Type: Article

References (15)

1. Hippius H. The history of clozapine. Psychopharmacolngy 1989; 99:S3-S5.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozaril Collaborative Study Group. Clozapine for the treatment-resistent schizophrenic: result of a US multicenter trial. Psychopharmacology 1989;99:60-63.
3. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Phamacol 1984;103:197-204.
4. Kane JM, Cooper TB, Sauchar EJ, et al. Clozapine: plasma levels and prolactine response. Psychopharmacology 1981;73:184-187.
5. Choc MG, Lehr RG, Hsuan F, et al. Multi-dose pharmacokinetics of clozapine in patients. Pharmaceutical Research 1987;4:402-405.
6. Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology 1989;99(suppl):S38-S40.
7. Goff DC, Henderson DC, Amico E, Cigarette Smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-1194.
8. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer H. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J Clin Psychopharmacol 1993;13:383-390.
9. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-374.
10. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996;41:605-608.
11. Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 1998;18:311-316.
12. Simpson GM, Cooper TA. Clozapine plasma concentrations and convulsions. Am J Psychiatry 1978;135:99-100.
13. Allebäck P, Wjstedt B. Mortality in schizophrenia. Arch Gen Psychiatry 1986;43:650-653.
14. Balant-Gorgia AE, Balant LP, Andreoli A. Pharmacokinetic optimization of the treatment of psychosis. Clin Pharmacokinet 1993; 25:217-236.
15. Miller D, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: A follow-up study. J Clin Psychiatry 1994;55(suppl B):117-121.